Tag Archives: AXGT

Chardan Capital Thinks Axovant Gene Therapies’ Stock is Going to Recover

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Axovant Gene Therapies (AXGT – Research Report) today and set a price target of $13.50. The company’s shares closed last Wednesday at $2.67, close to its 52-week low of $1.41.

Oppenheimer Keeps a Hold Rating on Axovant Gene Therapies (AXGT)

Oppenheimer analyst Jay Olson maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report) today. The company’s shares closed last Monday at $4.14, close to its 52-week low of $3.55. According to TipRanks.com, Olson is ranked 0 out

Cowen & Co. Maintains a Hold Rating on Axovant Gene Therapies (AXGT)

In a report released today, Ritu Baral from Cowen & Co. maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report). The company’s shares opened today at $6.43, close to its 52-week low of $3.81. According to TipRanks.com,

Analysts Offer Insights on Healthcare Companies: Axovant Gene Therapies (NASDAQ: AXGT) and Amgen Inc (NASDAQ: AMGN)

Analysts fell to the sidelines weighing in on Axovant Gene Therapies (AXGT – Research Report) and Amgen Inc (AMGN – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Axovant Gene Therapies

Axovant Gene Therapies (AXGT) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report) today. The company’s shares closed yesterday at $1.31, close to its 52-week low of $0.93. Olson observed: “AXGT hosted an R&D day featuring valuable

H.C. Wainwright Thinks Axovant Gene Therapies’ Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Axovant Gene Therapies (AXGT – Research Report), with a price target of $7. The company’s shares closed yesterday at $1.69, close to its 52-week low